Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia

Jordaens, Stephanie; Cooksey, Leah; Bonney, Stephanie; Orchard, Laurence; Coutinho, Matthew; Van Tendeloo, Viggo; Mills, Ken I.; Orchard, Kim; Guinn, Barbara

doi:10.1111/bjh.16407

All Outputs (2)

Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., …Guinn, B. (2020). Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80% of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum profiling identifies ibrutinib as a treatment option for young adults with B‐cell acute lymphoblastic leukaemia.

Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia (2020)
Journal Article
Jordaens, S., Cooksey, L., Bonney, S., Orchard, L., Coutinho, M., Van Tendeloo, V., …Guinn, B. (2020). Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia. British journal of haematology, 189(3), 500-512. https://doi.org/10.1111/bjh.16407

Acute lymphoblastic leukaemia (ALL) is a haematological malignancy that is characterized by the uncontrolled proliferation of immature lymphocytes. 80 % of cases occur in children where ALL is well understood and treated. However it has a devastating... Read More about Serum-profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.